Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1236-1245

  Ducreux, M ^a   Adenis, A ^b   Pignon, J P ^a   Francois E ^c   Chauffert, B ^d   Ichante J L ^a   Boucher, E ^e   Ychou, M ^f   Pierga, J Y ^g   Montoto Grillot, C ^h   Conroy, T ⁱ  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f CENTRE VAL D AURELLE   (France)

^g INSTITUT CURIE   (France)

^h UNICANCER   (France)

ⁱ CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Bevacizumab; Capecitabine; Colorectal neoplasms; Fluorouracil; Irinotecan; Quality of life; Randomised controlled trial

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CANCER FATIGUE; CANCER PROGNOSIS; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FISTULA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; NEUTROPENIA; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84875727313     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.12.011     Document Type: Article

References (20)

1. J. Cassidy, S. Clarke, and E. Díaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
2. M.L. Rothenberg, J.V. Cox, and C. Butts Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study Ann Oncol 19 2008 1720 1726
3. M. Ducreux, J. Bennouna, and M. Hebbar Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer Int J Cancer 128 2011 682 690
4. E. Díaz-Rubio, J. Tabernero, and A. Gómez-España Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial J Clin Oncol 25 2007 4224 4230
5. L.B. Saltz, S. Clarke, and E. Díaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
6. J. Tol, M. Koopman, and C.J. Rodenburg A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity Ann Oncol 19 2008 734 738
7. H.S. Hochster, L.L. Hart, and R.K. Ramanathan Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 2008 3523 3529
8. B. Gruenberger, D. Tamandl, and J. Schueller Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 26 2008 1830 1835
9. M. Koopman, N.F. Antonini, and J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142
10. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 2007 4779 4786
11. C.H. Köhne, J. De Greve, and J.T. Hartmann Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann Oncol 19 2008 920 926
12. A. Ardavanis, P. Kountourakis, and I. Mantzaris Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen Anticancer Res 28 2008 3087 3092
13. M. Moehler, M.F. Sprinzl, and M. Abdelfattah Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients World J Gastroenterol 15 2009 449 456
14. D.J. Renouf, S. Welch, and M.J. Moore A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer Cancer Chemother Pharmacol 69 2012 1339 1344
15. M. Ducreux, D. Malka, and J. Mendiboure Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial Lancet Oncol 12 2011 1032 1044
16. J. Souglakos, N. Ziras, and S. Kakolyris Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) Br J Cancer 106 2012 453 459
17. D. Arnold, T. Andre, and J. Bennouna Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study) J Clin Oncol 30 suppl; abstr. CRA3503 2012
18. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
19. A.L. Cohn, T. Bekaii-Saab, and J.C. Bendell Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) J Clin Oncol 28 2010 7s (suppl; abstr. 3596)
20. A.C. Reinacher-Schick, S. Kubicka, and W. Freier Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) J Clin Oncol 26 2008 (suppl 15S abstr 4030)